Quality of life in fit elderly patients with chronic lymphocytic leukemia (CLL) receiving oral fludarabine-based regimens as first line therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial.

被引：0
|
作者：
Sandhu, Suneet [1 ,2 ]
Gill, Devinder [1 ,2 ]
Turner, Paul [1 ,2 ]
Renwick, William [1 ,2 ]
Latimer, Maya [1 ,2 ]
Mackinlay, Naomi [1 ,2 ]
Berkahn, Leanne [1 ,2 ]
Simpson, David [1 ,2 ]
Campbell, Phillip [1 ,2 ]
Forsyth, Cecily [1 ,2 ]
Cull, Gavin [1 ,2 ]
Harrup, Rosemary [1 ,2 ]
Sulda, Melanie [1 ,2 ]
Best, Giles [1 ,2 ]
Bressel, Mathias [1 ,2 ]
Di Iulio, Juliana [1 ,2 ]
Kuss, Bryone [1 ,2 ]
Mulligan, Stephen [1 ,2 ]
机构：
[1] Australasian Leukaemia & Lymphoma Grp, Richmond, Vic, Australia
[2] Chron Lymphocyt Leukemia Australian Res Consortiu, Richmond, Vic, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34
引用
收藏
页码：27 / 29
页数：3
相关论文
共 32 条
  • [21] Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    Eichhorst, Barbara F.
    Bahlo, Jasmin
    Maurer, Christian
    Lange, Elisabeth
    Koppler, Hubert
    Kiehl, Michael G.
    Sokler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Kochling, Georg
    Ploger, Christoph
    Gregor, Michael
    Plesner, Torben
    Herling, Marco
    Fischer, Kirsten
    Dohner, Hartmut
    Kneba, Michael
    Wendtner, Clemens
    Klapper, Wolfram
    Kreuzer, Karl-Anton
    Bottcher, Sebastian
    Stilgenbauer, Stephan
    Fink, Anna Maria
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [22] First line therapy of patients (pts) with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG).
    Schmitt, BF
    Kneba, M
    Ritgen, M
    Stauch, M
    Emmerich, B
    Bergmann, M
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2002, 100 (11) : 387A - 387A
  • [23] A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity
    Mulligan, Stephen P.
    Gill, Devinder
    Turner, Paul
    Renwick, William E. P.
    Latimer, Maya
    Mackinlay, Naomi
    Berkahn, Leanne
    Simpson, David
    Campbell, Philip
    Forsyth, Cecily J.
    Cull, Gavin
    Harrup, Rosemary
    Sulda, Melanie
    Best, Giles
    Bressel, Mathias
    Di Iulio, Juliana
    Kuss, Bryone J.
    BLOOD, 2014, 124 (21)
  • [24] No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (C1b) in elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL):: Results of a phase III study of the German CLL study group (GCLLSG)
    Eichhorst, Barbara F.
    Busch, Raymonde
    Stauch, Martina
    Bergmann, Manuela
    Ritgen, Matthias
    Kranzhofer, Nicole
    Schweighofer, Carmen D.
    Fischer, Kirsten
    Fink, Anna-Maria
    Cramer, Paula
    Goede, Valentin
    Wendtner, Clemens M.
    Hallek, Michael
    BLOOD, 2007, 110 (11) : 194A - 194A
  • [25] Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): Results of a meta-analysis of two phase III trials of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2005, 106 (11) : 213A - 213A
  • [26] Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil:: Interim analysis of a phase III study of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Stauch, M
    Kneba, M
    Ritgen, M
    Söling, U
    Burkhard, O
    Bergmann, M
    Wendtner, CM
    Hiddemann, W
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 109A - 109A
  • [27] Dose-reduced FCR first-line therapy in fit elderly CLL patients is safe, tolerable, and highly effective; first report of final statistical analysis from end of study and 12 month follow-up of ALLG CLL5 randomised dose de-escalation study
    Mulligan, Stephen
    Turner, Paul
    Gill, Devinder
    Latimer, Maya
    Renwick, William
    Harrup, Rosemary
    Cull, Gavin
    Forsyth, Cecily
    Mackinlay, Naomi
    Berkahn, Leanne
    Campbell, Phillip
    Simpson, David
    Tam, Constantine
    Sulda, Melanie
    Best, Giles
    Bressel, Mathias
    Di Iulio, Juliana
    Kuss, Bryone
    LEUKEMIA & LYMPHOMA, 2015, 56 : 23 - 24
  • [28] Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of younger patients (PTS) with chronic lymphocytic leukemia (CLL): Results of a phase III study of the German CLL Study Group (GCLLSG)
    Eichhorst, B
    Busch, R
    Emmerich, B
    Hallek, M
    ANNALS OF ONCOLOGY, 2005, 16 : 89 - 90
  • [29] First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group
    Hallek, Michael
    Fingerle-Rowson, Guenter
    Fink, Anna-Maria
    Busch, Raymonde
    Mayer, Jiri
    Hensel, Manfred
    Hopfinger, Georg
    Hess, Georg
    von Gruenhagen, Ulrich
    Bergmann, Manuela A.
    Catalano, John
    Zinzano, Pier Luigi
    Cappio, Federico Caligaris
    Seymour, John F.
    Berrebi, Alain
    Jaeger, Ulrich
    Cazin, Bruno
    Trneny, Marek
    Westermann, Anne
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Staib, Peter
    Boettcher, Sebastian
    Ritgen, Matthias
    Mendila, Myriam
    Kneba, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Fischer, Kirsten
    BLOOD, 2009, 114 (22) : 223 - 224
  • [30] Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC plus G) Versus Chlorambucil Plus Obinutuzumab (Cbl plus G) As Front-Line Therapy
    Mulligan, Stephen P.
    Freeman, Jane A.
    Badoux, Xavier
    Eek, Richard
    Cull, Gavin
    Mackinlay, Naomi J.
    Murphy, Nicholas E.
    Carradice, Duncan P.
    Solterbeck, Ann C.
    Best, Oliver Giles
    Tam, Constantine S.
    Kuss, Bryone J.
    BLOOD, 2018, 132
1234